APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

ERA Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global ERA Drugs Industry Growth and Trends Forecast to 2032

Report ID 173989190128 December 2025103 pages

Choose your research edition.

Industry ResearchERA Drugs Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal ERA Drugs Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal ERA Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal ERA Drugs Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal ERA Drugs Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global ERA Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for ERA Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for ERA Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for ERA Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of ERA Drugs include Dr. Reddy's Laboratories, Gilead Sciences, Mylan, Teva, United Therapeutics, Hangzhou Zhongmei Huadong Pharmaceutical, Jiangsu Yunyang Group Pharmaceutical, Qilu Pharmaceutical and Johnson & Johnson, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global ERA Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The ERA Drugs market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global ERA Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to ERA Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global ERA Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

ERA Drugs Market by Company

Dr. Reddy's Laboratories

Gilead Sciences

Mylan

Teva

United Therapeutics

Hangzhou Zhongmei Huadong Pharmaceutical

Jiangsu Yunyang Group Pharmaceutical

Qilu Pharmaceutical

Johnson & Johnson

Shanghai Xudong Haipu Pharmaceutical

Shanghai Pharmaceutical Group

Sinotherapeutics

Zhengda Tianqing

ERA Drugs Segment by Type

Ambrisentan

Bosentan

Macitentan

ERA Drugs Segment by Application

Hospital

Clinic

Other

ERA Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global ERA Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of ERA Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of ERA Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of ERA Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of ERA Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Ambrisentan Table 2. Major Company of Bosentan Table 3. Major Company of Macitentan Table 4. Global ERA Drugs Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global ERA Drugs Sales by Type (2021-2026) & (K Units) Table 6. Global ERA Drugs Sales Market Share in Volume by Type (2021-2026) Table 7. Global ERA Drugs Sales by Type (2021-2026) & (US$ Million) Table 8. Global ERA Drugs Sales Market Share in Value by Type (2021-2026) Table 9. Global ERA Drugs Price by Type (2021-2026) & (US$/Unit) Table 10. Global ERA Drugs Sales by Type (2027-2032) & (K Units) Table 11. Global ERA Drugs Sales Market Share in Volume by Type (2027-2032) Table 12. Global ERA Drugs Sales by Type (2027-2032) & (US$ Million) Table 13. Global ERA Drugs Sales Market Share in Value by Type (2027-2032) Table 14. Global ERA Drugs Price by Type (2027-2032) & (US$/Unit) Table 15. North America ERA Drugs Sales by Type (2021-2026) & (K Units) Table 16. North America ERA Drugs Sales by Type (2021-2026) & (US$ Million) Table 17. Europe ERA Drugs Sales by Type (2021-2026) & (K Units) Table 18. Europe ERA Drugs Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific ERA Drugs Sales by Type (2021-2026) & (K Units) Table 20. Asia-Pacific ERA Drugs Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America ERA Drugs Sales by Type (2021-2026) & (K Units) Table 22. Latin America ERA Drugs Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa ERA Drugs Sales by Type (2021-2026) & (K Units) Table 24. Middle East and Africa ERA Drugs Sales by Type (2021-2026) & (US$ Million) Table 25. ERA Drugs Industry Trends Table 26. ERA Drugs Industry Drivers Table 27. ERA Drugs Industry Opportunities and Challenges Table 28. ERA Drugs Industry Restraints Table 29. Global ERA Drugs Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global ERA Drugs Revenue Market Share by Company (2021-2026) Table 31. Global ERA Drugs Sales by Company (2021-2026) & (K Units) Table 32. Global ERA Drugs Sales Share by Company (2021-2026) Table 33. Global ERA Drugs Market Price by Company (2021-2026) & (US$/Unit) Table 34. Global ERA Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global ERA Drugs Major Company Production Sites and Headquarters Table 36. Global ERA Drugs Company, Product Type & Application Table 37. Global ERA Drugs Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global ERA Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global ERA Drugs Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global ERA Drugs Sales by Region (2021-2026) & (K Units) Table 42. Global ERA Drugs Sales Market Share in Volume by Region (2021-2026) Table 43. Global ERA Drugs Sales by Region (2021-2026) & (US$ Million) Table 44. Global ERA Drugs Sales Market Share in Value by Region (2021-2026) Table 45. Global ERA Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Global ERA Drugs Sales by Region (2027-2032) & (K Units) Table 47. Global ERA Drugs Sales Market Share in Volume by Region (2027-2032) Table 48. Global ERA Drugs Sales by Region (2027-2032) & (US$ Million) Table 49. Global ERA Drugs Sales Market Share in Value by Region (2027-2032) Table 50. Global ERA Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 51. Global ERA Drugs Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global ERA Drugs Sales by Application (2021-2026) & (K Units) Table 53. Global ERA Drugs Sales Market Share in Volume by Application (2021-2026) Table 54. Global ERA Drugs Sales by Application (2021-2026) & (US$ Million) Table 55. Global ERA Drugs Sales Market Share in Value by Application (2021-2026) Table 56. Global ERA Drugs Price by Application (2021-2026) & (US$/Unit) Table 57. Global ERA Drugs Sales by Application (2027-2032) & (K Units) Table 58. Global ERA Drugs Sales Market Share in Volume by Application (2027-2032) Table 59. Global ERA Drugs Sales by Application (2027-2032) & (US$ Million) Table 60. Global ERA Drugs Sales Market Share in Value by Application (2027-2032) Table 61. Global ERA Drugs Price by Application (2027-2032) & (US$/Unit) Table 62. North America ERA Drugs Sales by Application (2021-2026) & (K Units) Table 63. North America ERA Drugs Sales by Application (2021-2026) & (US$ Million) Table 64. Europe ERA Drugs Sales by Application (2021-2026) & (K Units) Table 65. Europe ERA Drugs Sales by Application (2021-2026) & (US$ Million) Table 66. Asia-Pacific ERA Drugs Sales by Application (2021-2026) & (K Units) Table 67. Asia-Pacific ERA Drugs Sales by Application (2021-2026) & (US$ Million) Table 68. Latin America ERA Drugs Sales by Application (2021-2026) & (K Units) Table 69. Latin America ERA Drugs Sales by Application (2021-2026) & (US$ Million) Table 70. Middle East and Africa ERA Drugs Sales by Application (2021-2026) & (K Units) Table 71. Middle East and Africa ERA Drugs Sales by Application (2021-2026) & (US$ Million) Table 72. Dr. Reddy's Laboratories Company Information Table 73. Dr. Reddy's Laboratories Business Overview Table 74. Dr. Reddy's Laboratories ERA Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Dr. Reddy's Laboratories ERA Drugs Product Portfolio Table 76. Dr. Reddy's Laboratories Recent Development Table 77. Gilead Sciences Company Information Table 78. Gilead Sciences Business Overview Table 79. Gilead Sciences ERA Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Gilead Sciences ERA Drugs Product Portfolio Table 81. Gilead Sciences Recent Development Table 82. Mylan Company Information Table 83. Mylan Business Overview Table 84. Mylan ERA Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Mylan ERA Drugs Product Portfolio Table 86. Mylan Recent Development Table 87. Teva Company Information Table 88. Teva Business Overview Table 89. Teva ERA Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Teva ERA Drugs Product Portfolio Table 91. Teva Recent Development Table 92. United Therapeutics Company Information Table 93. United Therapeutics Business Overview Table 94. United Therapeutics ERA Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. United Therapeutics ERA Drugs Product Portfolio Table 96. United Therapeutics Recent Development Table 97. Hangzhou Zhongmei Huadong Pharmaceutical Company Information Table 98. Hangzhou Zhongmei Huadong Pharmaceutical Business Overview Table 99. Hangzhou Zhongmei Huadong Pharmaceutical ERA Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Hangzhou Zhongmei Huadong Pharmaceutical ERA Drugs Product Portfolio Table 101. Hangzhou Zhongmei Huadong Pharmaceutical Recent Development Table 102. Jiangsu Yunyang Group Pharmaceutical Company Information Table 103. Jiangsu Yunyang Group Pharmaceutical Business Overview Table 104. Jiangsu Yunyang Group Pharmaceutical ERA Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Jiangsu Yunyang Group Pharmaceutical ERA Drugs Product Portfolio Table 106. Jiangsu Yunyang Group Pharmaceutical Recent Development Table 107. Qilu Pharmaceutical Company Information Table 108. Qilu Pharmaceutical Business Overview Table 109. Qilu Pharmaceutical ERA Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Qilu Pharmaceutical ERA Drugs Product Portfolio Table 111. Qilu Pharmaceutical Recent Development Table 112. Johnson & Johnson Company Information Table 113. Johnson & Johnson Business Overview Table 114. Johnson & Johnson ERA Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Johnson & Johnson ERA Drugs Product Portfolio Table 116. Johnson & Johnson Recent Development Table 117. Shanghai Xudong Haipu Pharmaceutical Company Information Table 118. Shanghai Xudong Haipu Pharmaceutical Business Overview Table 119. Shanghai Xudong Haipu Pharmaceutical ERA Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Shanghai Xudong Haipu Pharmaceutical ERA Drugs Product Portfolio Table 121. Shanghai Xudong Haipu Pharmaceutical Recent Development Table 122. Shanghai Pharmaceutical Group Company Information Table 123. Shanghai Pharmaceutical Group Business Overview Table 124. Shanghai Pharmaceutical Group ERA Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Shanghai Pharmaceutical Group ERA Drugs Product Portfolio Table 126. Shanghai Pharmaceutical Group Recent Development Table 127. Sinotherapeutics Company Information Table 128. Sinotherapeutics Business Overview Table 129. Sinotherapeutics ERA Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. Sinotherapeutics ERA Drugs Product Portfolio Table 131. Sinotherapeutics Recent Development Table 132. Zhengda Tianqing Company Information Table 133. Zhengda Tianqing Business Overview Table 134. Zhengda Tianqing ERA Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. Zhengda Tianqing ERA Drugs Product Portfolio Table 136. Zhengda Tianqing Recent Development Table 137. North America ERA Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 138. North America ERA Drugs Sales by Country (2021-2026) & (K Units) Table 139. North America ERA Drugs Sales Market Share by Country (2021-2026) Table 140. North America ERA Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 141. North America ERA Drugs Sales Market Share Forecast by Country (2027-2032) Table 142. North America ERA Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 143. North America ERA Drugs Market Size by Country (2021-2026) & (US$ Million) Table 144. North America ERA Drugs Market Share by Country (2021-2026) Table 145. North America ERA Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 146. North America ERA Drugs Market Share Forecast by Country (2027-2032) Table 147. Europe ERA Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 148. Europe ERA Drugs Sales by Country (2021-2026) & (K Units) Table 149. Europe ERA Drugs Sales Market Share by Country (2021-2026) Table 150. Europe ERA Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 151. Europe ERA Drugs Sales Market Share Forecast by Country (2027-2032) Table 152. Europe ERA Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 153. Europe ERA Drugs Market Size by Country (2021-2026) & (US$ Million) Table 154. Europe ERA Drugs Market Share by Country (2021-2026) Table 155. Europe ERA Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 156. Europe ERA Drugs Market Share Forecast by Country (2027-2032) Table 157. Asia-Pacific ERA Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 158. Asia-Pacific ERA Drugs Sales by Country (2021-2026) & (K Units) Table 159. Asia-Pacific ERA Drugs Sales Market Share by Country (2021-2026) Table 160. Asia-Pacific ERA Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 161. Asia-Pacific ERA Drugs Sales Market Share Forecast by Country (2027-2032) Table 162. Asia-Pacific ERA Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 163. Asia-Pacific ERA Drugs Market Size by Country (2021-2026) & (US$ Million) Table 164. Asia-Pacific ERA Drugs Market Share by Country (2021-2026) Table 165. Asia-Pacific ERA Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 166. Asia-Pacific ERA Drugs Market Share Forecast by Country (2027-2032) Table 167. Latin America ERA Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 168. Latin America ERA Drugs Sales by Country (2021-2026) & (K Units) Table 169. Latin America ERA Drugs Sales Market Share by Country (2021-2026) Table 170. Latin America ERA Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 171. Latin America ERA Drugs Sales Market Share Forecast by Country (2027-2032) Table 172. Latin America ERA Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 173. Latin America ERA Drugs Market Size by Country (2021-2026) & (US$ Million) Table 174. Latin America ERA Drugs Market Share by Country (2021-2026) Table 175. Latin America ERA Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 176. Latin America ERA Drugs Market Share Forecast by Country (2027-2032) Table 177. Middle East and Africa ERA Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 178. Middle East and Africa ERA Drugs Sales by Country (2021-2026) & (K Units) Table 179. Middle East and Africa ERA Drugs Sales Market Share by Country (2021-2026) Table 180. Middle East and Africa ERA Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 181. Middle East and Africa ERA Drugs Sales Market Share Forecast by Country (2027-2032) Table 182. Middle East and Africa ERA Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 183. Middle East and Africa ERA Drugs Market Size by Country (2021-2026) & (US$ Million) Table 184. Middle East and Africa ERA Drugs Market Share by Country (2021-2026) Table 185. Middle East and Africa ERA Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 186. Middle East and Africa ERA Drugs Market Share Forecast by Country (2027-2032) Table 187. Key Raw Materials Table 188. Raw Materials Key Suppliers Table 189. ERA Drugs Distributors List Table 190. ERA Drugs Customers List Table 191. Research Programs/Design for This Report Table 192. Authors List of This Report Table 193. Secondary Sources Table 194. Primary Sources List of Figures Figure 1. ERA Drugs Image Figure 2. Global ERA Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global ERA Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global ERA Drugs Sales (2021-2032) & (K Units) Figure 5. Ambrisentan Image Figure 6. Global Ambrisentan Sales YoY Growth (2021-2032) & (K Units) Figure 7. Bosentan Image Figure 8. Global Bosentan Sales YoY Growth (2021-2032) & (K Units) Figure 9. Macitentan Image Figure 10. Global Macitentan Sales YoY Growth (2021-2032) & (K Units) Figure 11. Global ERA Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 12. Global ERA Drugs Market Share by Type 2025 VS 2032 Figure 13. North America ERA Drugs Sales Market Share in Volume by Type in 2025 Figure 14. North America ERA Drugs Sales Market Share in Value by Type in 2025 Figure 15. Europe ERA Drugs Sales Market Share in Volume by Type in 2025 Figure 16. Europe ERA Drugs Sales Market Share in Value by Type in 2025 Figure 17. Asia-Pacific ERA Drugs Sales Market Share in Volume by Type in 2025 Figure 18. Asia-Pacific ERA Drugs Sales Market Share in Value by Type in 2025 Figure 19. Latin America ERA Drugs Sales Market Share in Volume by Type in 2025 Figure 20. Latin America ERA Drugs Sales Market Share in Value by Type in 2025 Figure 21. Middle East and Africa ERA Drugs Sales Market Share in Volume by Type in 2025 Figure 22. Middle East and Africa ERA Drugs Sales Market Share in Value by Type in 2025 Figure 23. Global Top 5 and 10 ERA Drugs Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Hospital Image Figure 26. Global Hospital Sales YoY Growth (2021-2032) & (K Units) Figure 27. Clinic Image Figure 28. Global Clinic Sales YoY Growth (2021-2032) & (K Units) Figure 29. Other Image Figure 30. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 31. Global ERA Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global ERA Drugs Market Share by Application 2025 VS 2032 Figure 33. North America ERA Drugs Sales Market Share in Volume by Application in 2025 Figure 34. North America ERA Drugs Sales Market Share in Value by Application in 2025 Figure 35. Europe ERA Drugs Sales Market Share in Volume by Application in 2025 Figure 36. Europe ERA Drugs Sales Market Share in Value by Application in 2025 Figure 37. Asia-Pacific ERA Drugs Sales Market Share in Volume by Application in 2025 Figure 38. Asia-Pacific ERA Drugs Sales Market Share in Value by Application in 2025 Figure 39. Latin America ERA Drugs Sales Market Share in Volume by Application in 2025 Figure 40. Latin America ERA Drugs Sales Market Share in Value by Application in 2025 Figure 41. Middle East and Africa ERA Drugs Sales Market Share in Volume by Application in 2025 Figure 42. Middle East and Africa ERA Drugs Sales Market Share in Value by Application in 2025 Figure 43. North America ERA Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 44. North America ERA Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. North America ERA Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. North America ERA Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe ERA Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 48. Europe ERA Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe ERA Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe ERA Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific ERA Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. Asia-Pacific ERA Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific ERA Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Asia-Pacific ERA Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America ERA Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Latin America ERA Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America ERA Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Latin America ERA Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa ERA Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 60. Middle East and Africa ERA Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa ERA Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Middle East and Africa ERA Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. ERA Drugs Value Chain Figure 64. Key Raw Materials Price Figure 65. Manufacturing Cost Structure Figure 66. ERA Drugs Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Ambrisentan
  • Bosentan
  • Macitentan
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Dr. Reddy's Laboratories
  • Gilead Sciences
  • Mylan
  • Teva
  • United Therapeutics
  • Hangzhou Zhongmei Huadong Pharmaceutical
  • Jiangsu Yunyang Group Pharmaceutical
  • Qilu Pharmaceutical
  • Johnson & Johnson
  • Shanghai Xudong Haipu Pharmaceutical
  • Shanghai Pharmaceutical Group
  • Sinotherapeutics
  • Zhengda Tianqing

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global ERA Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global ERA Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.3 ERA Drugs Market by Type
  6. 1.3.1 Ambrisentan
  7. 1.3.2 Bosentan
  8. 1.3.3 Macitentan
  9. 1.4 Global ERA Drugs Market Size by Type
  10. 1.4.1 Global ERA Drugs Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global ERA Drugs Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global ERA Drugs Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America ERA Drugs Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe ERA Drugs Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific ERA Drugs Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America ERA Drugs Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa ERA Drugs Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 ERA Drugs Industry Trends
  2. 2.2 ERA Drugs Industry Drivers
  3. 2.3 ERA Drugs Industry Opportunities and Challenges
  4. 2.4 ERA Drugs Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by ERA Drugs Revenue (2021-2026)
  2. 3.2 Global Top Players by ERA Drugs Sales (2021-2026)
  3. 3.3 Global Top Players by ERA Drugs Price (2021-2026)
  4. 3.4 Global ERA Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global ERA Drugs Major Company Production Sites & Headquarters
  6. 3.6 Global ERA Drugs Company, Product Type & Application
  7. 3.7 Global ERA Drugs Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global ERA Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 ERA Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 ERA Drugs Tier 1, Tier 2, and Tier 3
4 ERA Drugs Regional Status and Outlook
  1. 4.1 Global ERA Drugs Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global ERA Drugs Historic Market Size by Region
  3. 4.2.1 Global ERA Drugs Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global ERA Drugs Sales in Value by Region (2021-2026)
  5. 4.2.3 Global ERA Drugs Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global ERA Drugs Forecasted Market Size by Region
  7. 4.3.1 Global ERA Drugs Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global ERA Drugs Sales in Value by Region (2027-2032)
  9. 4.3.3 Global ERA Drugs Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 ERA Drugs by Application
  1. 5.1 ERA Drugs Market by Application
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global ERA Drugs Market Size by Application
  6. 5.2.1 Global ERA Drugs Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global ERA Drugs Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global ERA Drugs Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America ERA Drugs Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe ERA Drugs Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific ERA Drugs Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America ERA Drugs Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa ERA Drugs Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Dr. Reddy's Laboratories
  2. 6.1.1 Dr. Reddy's Laboratories Company Information
  3. 6.1.2 Dr. Reddy's Laboratories Business Overview
  4. 6.1.3 Dr. Reddy's Laboratories ERA Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Dr. Reddy's Laboratories ERA Drugs Product Portfolio
  6. 6.1.5 Dr. Reddy's Laboratories Recent Developments
  7. 6.2 Gilead Sciences
  8. 6.2.1 Gilead Sciences Company Information
  9. 6.2.2 Gilead Sciences Business Overview
  10. 6.2.3 Gilead Sciences ERA Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Gilead Sciences ERA Drugs Product Portfolio
  12. 6.2.5 Gilead Sciences Recent Developments
  13. 6.3 Mylan
  14. 6.3.1 Mylan Company Information
  15. 6.3.2 Mylan Business Overview
  16. 6.3.3 Mylan ERA Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Mylan ERA Drugs Product Portfolio
  18. 6.3.5 Mylan Recent Developments
  19. 6.4 Teva
  20. 6.4.1 Teva Company Information
  21. 6.4.2 Teva Business Overview
  22. 6.4.3 Teva ERA Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Teva ERA Drugs Product Portfolio
  24. 6.4.5 Teva Recent Developments
  25. 6.5 United Therapeutics
  26. 6.5.1 United Therapeutics Company Information
  27. 6.5.2 United Therapeutics Business Overview
  28. 6.5.3 United Therapeutics ERA Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 United Therapeutics ERA Drugs Product Portfolio
  30. 6.5.5 United Therapeutics Recent Developments
  31. 6.6 Hangzhou Zhongmei Huadong Pharmaceutical
  32. 6.6.1 Hangzhou Zhongmei Huadong Pharmaceutical Company Information
  33. 6.6.2 Hangzhou Zhongmei Huadong Pharmaceutical Business Overview
  34. 6.6.3 Hangzhou Zhongmei Huadong Pharmaceutical ERA Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Hangzhou Zhongmei Huadong Pharmaceutical ERA Drugs Product Portfolio
  36. 6.6.5 Hangzhou Zhongmei Huadong Pharmaceutical Recent Developments
  37. 6.7 Jiangsu Yunyang Group Pharmaceutical
  38. 6.7.1 Jiangsu Yunyang Group Pharmaceutical Company Information
  39. 6.7.2 Jiangsu Yunyang Group Pharmaceutical Business Overview
  40. 6.7.3 Jiangsu Yunyang Group Pharmaceutical ERA Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Jiangsu Yunyang Group Pharmaceutical ERA Drugs Product Portfolio
  42. 6.7.5 Jiangsu Yunyang Group Pharmaceutical Recent Developments
  43. 6.8 Qilu Pharmaceutical
  44. 6.8.1 Qilu Pharmaceutical Company Information
  45. 6.8.2 Qilu Pharmaceutical Business Overview
  46. 6.8.3 Qilu Pharmaceutical ERA Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Qilu Pharmaceutical ERA Drugs Product Portfolio
  48. 6.8.5 Qilu Pharmaceutical Recent Developments
  49. 6.9 Johnson & Johnson
  50. 6.9.1 Johnson & Johnson Company Information
  51. 6.9.2 Johnson & Johnson Business Overview
  52. 6.9.3 Johnson & Johnson ERA Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Johnson & Johnson ERA Drugs Product Portfolio
  54. 6.9.5 Johnson & Johnson Recent Developments
  55. 6.10 Shanghai Xudong Haipu Pharmaceutical
  56. 6.10.1 Shanghai Xudong Haipu Pharmaceutical Company Information
  57. 6.10.2 Shanghai Xudong Haipu Pharmaceutical Business Overview
  58. 6.10.3 Shanghai Xudong Haipu Pharmaceutical ERA Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Shanghai Xudong Haipu Pharmaceutical ERA Drugs Product Portfolio
  60. 6.10.5 Shanghai Xudong Haipu Pharmaceutical Recent Developments
  61. 6.11 Shanghai Pharmaceutical Group
  62. 6.11.1 Shanghai Pharmaceutical Group Company Information
  63. 6.11.2 Shanghai Pharmaceutical Group Business Overview
  64. 6.11.3 Shanghai Pharmaceutical Group ERA Drugs Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Shanghai Pharmaceutical Group ERA Drugs Product Portfolio
  66. 6.11.5 Shanghai Pharmaceutical Group Recent Developments
  67. 6.12 Sinotherapeutics
  68. 6.12.1 Sinotherapeutics Company Information
  69. 6.12.2 Sinotherapeutics Business Overview
  70. 6.12.3 Sinotherapeutics ERA Drugs Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Sinotherapeutics ERA Drugs Product Portfolio
  72. 6.12.5 Sinotherapeutics Recent Developments
  73. 6.13 Zhengda Tianqing
  74. 6.13.1 Zhengda Tianqing Company Information
  75. 6.13.2 Zhengda Tianqing Business Overview
  76. 6.13.3 Zhengda Tianqing ERA Drugs Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Zhengda Tianqing ERA Drugs Product Portfolio
  78. 6.13.5 Zhengda Tianqing Recent Developments
7 North America by Country
  1. 7.1 North America ERA Drugs Sales by Country
  2. 7.1.1 North America ERA Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America ERA Drugs Sales by Country (2021-2026)
  4. 7.1.3 North America ERA Drugs Sales Forecast by Country (2027-2032)
  5. 7.2 North America ERA Drugs Market Size by Country
  6. 7.2.1 North America ERA Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America ERA Drugs Market Size by Country (2021-2026)
  8. 7.2.3 North America ERA Drugs Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe ERA Drugs Sales by Country
  2. 8.1.1 Europe ERA Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe ERA Drugs Sales by Country (2021-2026)
  4. 8.1.3 Europe ERA Drugs Sales Forecast by Country (2027-2032)
  5. 8.2 Europe ERA Drugs Market Size by Country
  6. 8.2.1 Europe ERA Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe ERA Drugs Market Size by Country (2021-2026)
  8. 8.2.3 Europe ERA Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific ERA Drugs Sales by Country
  2. 9.1.1 Asia-Pacific ERA Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific ERA Drugs Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific ERA Drugs Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific ERA Drugs Market Size by Country
  6. 9.2.1 Asia-Pacific ERA Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific ERA Drugs Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific ERA Drugs Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America ERA Drugs Sales by Country
  2. 10.1.1 South America ERA Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America ERA Drugs Sales by Country (2021-2026)
  4. 10.1.3 South America ERA Drugs Sales Forecast by Country (2027-2032)
  5. 10.2 South America ERA Drugs Market Size by Country
  6. 10.2.1 South America ERA Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America ERA Drugs Market Size by Country (2021-2026)
  8. 10.2.3 South America ERA Drugs Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa ERA Drugs Sales by Country
  2. 11.1.1 Middle East and Africa ERA Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa ERA Drugs Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa ERA Drugs Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa ERA Drugs Market Size by Country
  6. 11.2.1 Middle East and Africa ERA Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa ERA Drugs Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa ERA Drugs Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 ERA Drugs Value Chain Analysis
  2. 12.1.1 ERA Drugs Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 ERA Drugs Production Mode & Process
  7. 12.2 ERA Drugs Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 ERA Drugs Distributors
  10. 12.2.3 ERA Drugs Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst